Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q38739807

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer.

@en

type

Item

label

Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer.

@en

prefLabel

Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer.

@en

P1476

Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer.

@en

P2093

David Planchard

http://www.w3.org/2001/XMLSchema#string

Ivana Sullivan

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

P304

945-961

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.16.15

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26892300

http://www.w3.org/2001/XMLSchema#string